Biotech Values

[makingmoneynow]

Hi Biocqr,

I am not sure how much you know about $ICOTF or ICo Therapeutics, but I can tell you that I have known this Co for 5 years and have been in and out twice before finally putting lots of dollars almost 18 months ago.

The problem that iCo has had was that it is one of the largest US based trials done by a Company that does not trade there. The Company has changed that last December by getting listed on the US QX exchange, but still pending DTC.

The idea of being a Canadian biotech and trying to get a Vancouver crowd to give proper valuation has proven to be weak and hence the migration to the US side. The Company started a run earlier this year, which was stalled by a financing that gives the Company enough cash to run to Q4 2015. The funding came through 3 US based funds and it was done through HC Wainright.

http://www.hcwainwright.com/

If you check HC's transactions, you will see that they only take high profile mandates.

If you look at what they have to with Rexhan or IGX tech our of Canada you can see how powerful they can be.

See below who bought in that latest financing and that may give you more comfort.

Happy to discuss more.

MMN

Class of securities reported upon Part 4 of National Instrument 62-103 The Early
Warning System and Related Take-Over Bid and Insider Reporting Issues:
Common Shares (“Shares”) of iCo Therapeutics Inc. (“iCo”).
(a) Name and address of the eligible institutional investor:
AWM Investment Company, Inc. (“AWM”)
527 Madison Avenue, Suite 2600
New York, New York 10022

(b) Net increase or decrease in the number or principal amount of securities,
and in the eligible institutional investor’s securityholding percentage in
the class of securities, since the last report filed by the eligible institutional
investor under Part 4 or the early warning requirements:
This is the initial report filed by AWM under Part 4 of NI 62-103. AWM
serves as investment advisor to Special Situations Fund III QP, L.P. and
Special Situations Life Sciences Fund, L.P. (the “Funds”). The Funds,
identified in paragraph (c) below, each advised by AWM, collectively
purchased 5,402,161 Shares and warrants to purchase 4,051,621 Shares, in an
offering that closed on January 27, 2014.
(c) The designation and number or principal amount of securities and the
eligible institutional investor’s securityholding percentage in the class of
securities at the end of the month for which the report is made:
10,487,161 Shares and warrants to purchase 4,051,621 Shares of iCo are held
by two funds (the “Funds”), which are advised by AWM, representing
approximately 16.5% of the issued and outstanding Shares as of January 27,
2014 following the completion of the offering and assuming the exercise in
full of all warrants held by the Funds.
Special Situations Fund III QP, L.P. owns 5,243,817 Shares and warrants to
purchase 2,025,811 Shares or approximately 8.4% of the Shares outstanding
assuming the exercise in full of all warrants held by it. Special Situations
Life Sciences Fund, L.P. owns 5,243,344 Shares and warrants to purchase
2,025,810 Shares or approximately 8.4% of the Shares outstanding assuming
the exercise in full of all warrants held by it.
(d) The designation and number or principal amount of securities and the
percentage of outstanding securities referred to in paragraph (c) over which
(i) the eligible institutional investor, either alone or together with any joint
actors, has ownership and control: 5610068 v1
- 2 -

The Funds own the Securities in question as indicated in paragraph (c) above,
and AWM controls such Securities, as investment advisor to the Funds.
(ii) the eligible institutional investor, either alone or together with any joint
actors, has ownership but control is held by other entities other than the
eligible institutional investor or any joint actor:
The Funds own the Shares in question as indicate in paragraph (c) above.
(iii) the eligible institutional investor, either alone or together with any joint
actors, has exclusive or shared control but does not have ownership:
The Securities of iCo as indicated in paragraph (c) above are controlled by
AWM, as investment advisor to the Funds.
(e) The purpose of the eligible institutional investor and any joint actors in
acquiring or disposing of ownership of, or control over, the securities,
including any future intention to acquire ownership of, or control over,
additional securities of the reporting issuer
AWM controls the Securities of iCo on behalf of the Funds for investment
purposes. AWM and/or the Funds may purchase additional Shares and/or
other securities, or dispose of Shares, and/or other securities, of iCo from
time to time as circumstances warrant.
(f) the general nature and the material terms of any agreement, other than
lending arrangements, with respect to securities of the reporting issuer
entered into by the eligible institutional investor, or any joint actor, and
the issuer of the securities or any other entity in connection with any
transaction or occurrence resulting in the change in ownership or control
giving rise to the report, including agreements with respect to the
acquisition, holding, disposition or voting of any securities:
Not applicable.
(g) the names of any joint actors in connection with the disclosure required
hereunder:
AWM and the Funds may be considered to act jointly or in concert.
(h) Description of any change in any material fact set out in a previous report
by the eligible institutional investor under the early warning requirements
or Part 4 in respect of the reporting issuer’s securities:
Not applicable.

5610068 v1
- 3 -


(i) Statement of Eligibility
AWM is eligible to file reports under Part 4 of NI 62-103 in respect of iCo.
DATED this __30th___ day of _____January___________, 2014.


AWM Investment Company, Inc.

By:
/s/ David M. Greenhouse
David M. Greenhouse
Title: Executive Vice President of AWM